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Abstract We report three cases which highlight the
complex considerations surrounding genetic counselling
for pulmonary arterial hypertension (PAH). The first
counselee developed PAH symptoms shortly after his
daughter’s death from PAH and was diagnosed with a
delay of 1 year. An early diagnosis of familial PAH was
established in the second counselee. Oral therapy was
initiated immediately, and her functional status has since
remained stable. The third counselee was a healthy woman
who struggled to cope with her risk for familial PAH,
having lost two siblings from the disease. These cases show
that incomplete penetrance and variable expression need
particular attention during clinical assessment and genetic
counselling of heritable PAH patients and family members.
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Introduction
Pulmonary arterial hypertension (PAH) is a devastating
disorder characterised by increased pulmonary vascular
resistance, ultimately leading to right heart failure and
premature death [1]. Recent evidence from a French
registry suggests that the prevalence of PAH is about 15
per million [2]. Despite major advances in the understand-
ing of the pathogenesis of PAH, none of the current
therapeutic approaches achieves a cure for this disorder
[3].
Different subtypes of PAH have been recognised such as
idiopathic PAH (IPAH), heritable PAH (HPAH) and forms
associated with various disorders. IPAH corresponds to
sporadic disease in which there is neither a family history of
PAH nor an identified associated disorder. HPAH includes
IPAH cases with germline mutations and familial cases with
or without identified germline mutations [4]. HPAH is
mainly related to mutations in the bone morphogenetic
protein (BMP) type II receptor gene (BMPR2), a member of
the transforming growth factor β signalling family [5, 6].
Mutations in the BMPR2 gene have been identified in
>70% of familial PAH and in approximately 20% of IPAH
cases [5–8]. BMPR2-related HPAH is an autosomal
dominant disorder which exhibits both incomplete pene-
trance (the percentage of individuals who have inherited a
germline mutation in the same gene expressing the
corresponding disorder to any degree is <100%) and
variable expression (variation in the severity of the disorder
in individuals who have inherited a germline mutation in
the same gene) [9]. Disease penetrance in case of a BMPR2
mutation ranges from 15% to 80% [10]. The variable
expression is reflected by for instance inter- and intra-
familial differences in age at disease onset and natural
history.
Genetic counselling is increasingly part of clinical
practise. Symptomatic and predictive (presymptomatic)
genetic testing is performed for a wide range of heritable
disorders characterised by different levels of penetrance
and/or expression. Incomplete penetrance and variable
expression need particular attention during clinical assess-
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ment and genetic counselling of HPAH patients and family
members. This is demonstrated by the three case reports
described below which highlight the complex considera-
tions surrounding genetic counselling for PAH.
Case Reports
Counselee A (Fig. 1a) is a man whose daughter had been
diagnosed with PAH at the age of 9 years. No underlying
cause was identified. In spite of treatment, disease severity
gradually worsened. She died of PAH at the age of 12.
Shortly after her death, counselee A himself developed
symptoms of fatigue and dyspnoea on exertion. He
consulted his family doctor who deemed it unlikely that
his symptoms could be attributed to PAH. Instead, the
symptoms were attributed to the coping process following
his daughter’s death. Eventually, after about 1 year,
counselee A was referred to our hospital where he was
diagnosed with PAH at the age of 39. No underlying cause
was identified. He was subsequently referred to the genetic
outpatient clinic. Symptomatic genetic testing of the
BMPR2 gene revealed a putative pathogenic germline
BMPR2 mutation. The same mutation was found in stored
DNA of his deceased daughter. Nearly 2 years after
counselee A had been diagnosed, he died at the age of 41
due to PAH.
Counselee B is a young healthy woman whose mother
was diagnosed with PAH at the age of 45 after several
years of progressive complaints of fatigue and dyspnoea.
A maternal cousin of her mother had died of PAH
(Fig. 1b). No underlying cause had been identified, and no
genetic testing of the BMPR2 gene had been performed in
the family. Following genetic counselling, a pathogenic
mutation in the BMPR2 gene was identified in the mother
of counselee B. Subsequently, both counselee B and her
healthy brother were referred to our genetic outpatient
clinic to discuss predictive testing. For both, the most
important reason for genetic testing was to learn about
their future children’s risk. Only counselee B was shown
to have inherited the familial BMPR2 mutation. Periodic
pulmonary and cardiological screenings were initiated.
Before her first pregnancy, she was examined thoroughly
and no signs of PAH were identified. Shortly after an
uncomplicated pregnancy and delivery, counselee B
developed progressive complaints of fatigue. Echocardi-
ography showed increased pressures in the pulmonary
artery. At the age of 27, PAH was confirmed by right heart
catheterisation. With oral medication, her functional status
has since remained stable for several years in New York
Heart Association class II.
Case C (Fig. 1c) relates to a healthy couple with two
daughters and one son. Two of their children had died of
PAH at 19 and 11 years of age, respectively. Before her
death, a pathogenic mutation in the BMPR2 gene was
identified in the daughter. On the basis of this result, the
conclusion seemed warranted that their son had also
inherited the same BMPR2 mutation. Therefore, the
mutation was either of paternal or maternal origin even
though both family branches did not include additional
cases of PAH. Predictive genetic testing was discussed with
the couple. Because of the medical history of their daughter
and son, genetic predisposition for PAH to them was
synonymous to developing PAH with a poor prognosis. For
this reason, they chose not to perform predictive genetic
testing. Shortly afterwards, their daughter approached our
clinic to discuss predictive genetic testing. The potential
advantage of screening was her most important reason for
genetic testing. She indicated that she would not discuss a
positive genetic test outcome with her parents because they
would interpret this as a poor prognosis for their only living
child. Following time for reflection, she decided to proceed
with predictive genetic testing. She was shown to have
inherited the familial BMPR2 mutation. Afterwards, she
had additional discussions with the genetic nurse and
pulmonologist about coping difficulties with regard to the
positive genetic test outcome. There has been no contact
with her since then.
Fig. 1 Pedigrees of counselee A, B and C. White square healthy man;
white circle healthy woman; black square and black circle man and
woman, respectively, diagnosed with heritable pulmonary arterial
hypertension; arrow counselee, solidus deceased)
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Discussion
Genetic counselling for PAH should be considered when no
underlying cause has been identified. It entails family
studies, discussion of the medical and genetic aspects of the
disorder and of genetic testing. A specialised social worker
or psychologist can support the decision and coping process
with regard to genetic testing for patients and healthy
family members. A genetic test result can be of great value.
When a BMPR2 mutation is identified, genetic predisposi-
tion is confirmed and predictive testing in family members
is possible. Relatives who test negative can be reassured.
On the other hand, healthy relatives who test positive are at
increased risk for developing PAH. They are informed
about the possible symptoms. Furthermore, periodic screen-
ing aimed at early diagnosis and treatment is warranted in
such individuals.
Data about the reasons for genetic testing in PAH are
scarcely available. The possible benefit of the outcome for
their children and/or other family members seems the most
important consideration for patients [11, 12]. No data are
available about the psychosocial aspects of genetic testing
for PAH.
In case of a positive family history, genetic predisposition
is certain even if it is not confirmed by a positive genetic test
outcome, i.e. a pathogenic BMPR2 mutation. This is because
it is highly unlikely that a relatively rare disease such as PAH
spontaneously affects two or more close relatives. Also, in
case of a negative family history, genetic predisposition is
not excluded by a negative test outcome. This is because it is
not certain that all BMPR2 mutations are identified by
current techniques. Moreover, it is possible that HPAH is
caused by mutations in another (yet unknown) gene.
A positive genetic test result currently does not have
consequences for the PAH patient. Recent reports have
related BMPR2 mutation status to specific clinical charac-
teristics. It is therefore anticipated that this status will have
therapeutic consequences in the near future [12, 13].
The incomplete penetrance and variable expression of
BMPR2-related HPAH may complicate considerations
surrounding genetic counselling. Although HPAH can
occur ‘de novo’, the low mean penetrance may obscure a
positive family history because the occurrence of disease
has skipped one or more generations. Moreover, the low
mean penetrance for a healthy individual who has inherited
a BMPR2 mutation should be weighed against the potential
negative consequences of such a positive genetic test
outcome for insurance and employment [14]. For healthy
family members of HPAH patients, it may be sufficient to
provide information about the symptoms of PAH. The
symptoms, however, are nonspecific which may neverthe-
less delay the diagnostic process [2, 15]. This is illustrated
by case A in which earlier knowledge about a potential role
of genetic predisposition in the family would likely have
resulted in earlier consideration of PAH as an explanation
for counselee A’s complaints. An early diagnosis on the
other hand was established in counselee B and treatment
was initiated immediately. Her functional status has since
remained stable. Whether early treatment in general leads to
a better prognosis to date is uncertain.
Intrafamilial variability is illustrated by all discussed cases.
The variability in age at disease onset is most prominently
illustrated by case A. For patients and family members, this
variability is difficult to comprehend. They seem to attach
value to the clinical manifestation in the first diagnosed
patient in the family, the patient with the least serious
manifestation of disease and/or the closest family member.
The discussed cases demonstrate that incomplete pene-
trance and variable expression need particular attention
during clinical assessment and genetic counselling of
HPAH patients and family members. Furthermore, it may
be preferable to offer the clinical genetic services in
specialised PAH centres.
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